Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Curr Mol Med ; 21(1): 2-4, 2021.
Article in English | MEDLINE | ID: covidwho-1154163

ABSTRACT

The COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1, MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic variants in NPC1, which encodes for the endo-lysosomal Niemann-Pick type C1 protein, restricts the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be explored.


Subject(s)
COVID-19/physiopathology , Intracellular Signaling Peptides and Proteins/physiology , SARS-CoV-2/physiology , Antiviral Agents/therapeutic use , COVID-19/virology , Drug Repositioning , Humans , Niemann-Pick C1 Protein , Severity of Illness Index , Virus Internalization , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL